Chalkias Athanasios, Mouzarou Angeliki, Samara Evangelia, Xanthos Theodoros, Ischaki Eleni, Pantazopoulos Ioannis
Department of Anesthesiology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larisa, Greece.
Department of Cardiology, General Hospital of Paphos, Paphos, Cyprus.
Mol Diagn Ther. 2020 Oct;24(5):517-521. doi: 10.1007/s40291-020-00481-8.
The novel coronavirus infection has spread worldwide, causing a wide spectrum of clinical manifestations. Most patients develop moderate clinical illness, but a substantial number will experience severe pneumonia, which may rapidly progress to acute respiratory distress syndrome and multiple organ failure. In this population, soluble urokinase plasminogen activator receptor (suPAR) could serve as a quick triage test and independent marker of clinical severity, hospital and intensive care unit admission, complications, and mortality.
新型冠状病毒感染已在全球范围内传播，导致广泛的临床表现。大多数患者出现中度临床疾病，但相当一部分患者会经历严重肺炎，这可能迅速发展为急性呼吸窘迫综合征和多器官功能衰竭。在这一人群中，可溶性尿激酶型纤溶酶原激活物受体（suPAR）可作为一种快速分诊检测指标，以及临床严重程度、住院和重症监护病房收治、并发症及死亡率的独立标志物。
